Search Results

You are looking at 191 - 200 of 2,734 items for :

  • Refine by Access: All x
Clear All
Full access

Testicular Cancer Survivorship

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

long-term adverse health outcomes (AHOs) among TCS is critically important for the development of risk-stratified, evidence-based follow-up guidelines. A multi-institutional study 40 among North American TCS (median age, 37 years) after cisplatin

Full access

HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting

Yu-Jing Huang, Paula D. Ryan, Gregory L. Price, Gebra Cuyun Carter, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Jonathan Rajkumar, and Lavanya Sudharshan

) patients (pts). This study examined real-world pt characteristics, select adverse events (AEs), and related outcomes of these pts. Methods: Female pts in the United States Oncology Network’s iKnowMedTM electronic health records (EHR) database were

Full access

CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy

Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales

Background: Although isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is relatively common, the optimal therapy for iLR is undefined. It is feasible that patients with iLR may have equal or superior outcomes to patients

Full access

HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population

Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu

mortality when compared to non-Asian patients with EGFR-positive NSCLC in a real-world US population. Further research is required to determine whether this association stems from a biological or non-biological cause. Table. Outcomes between AANHPI

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

-analysis calculations. Data Extraction and Outcomes Information recorded from each eligible trial included author names; journal; year of publication; number of centers involved; number of patients randomly assigned and analyzed per arm; years of patient

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

use in real-world settings are maturing, and critical pharmacovigilance of these products depends on the understanding of their use and clinical impact. 30 , 31 Similar clinical and safety outcomes of the G-CSF biosimilars compared with their

Full access

CGE21-031: Genomic Biomarker Testing, Treatments, and Survival Outcomes Among Patients With Advanced or Metastatic NSCLC in the US: A Retrospective Cohort Study

Yajun Zhu, Yimei Han, Naleen Raj Bhandari, and Lisa Hess

Objectives: This study identified factors associated with genomic biomarker testing (“tested” vs “not tested”) and examined the association of the receipt of treatment that is guided by genomic biomarker testing results with survival outcomes among

Full access

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea

-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using

Full access

CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review

David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal

studies with efficacy and safety outcomes with relevant interventions in patients with stage I-III MCC. The review included monotherapies or combinations of pharmacological treatments, radiotherapy (RT), chemotherapy (CT), and surgery (SUR). Adjuvant (adj

Full access

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride

real-world treatment patterns and outcomes in metastatic NSCLC patients treated with a first line (1L) therapy. Methods: A retrospective cohort analysis of IBM MarketScan@ Commercial and Medicare Supplemental Claims Databases was conducted. The